SE9904377D0 - Pharmaceutical combinations - Google Patents

Pharmaceutical combinations

Info

Publication number
SE9904377D0
SE9904377D0 SE9904377A SE9904377A SE9904377D0 SE 9904377 D0 SE9904377 D0 SE 9904377D0 SE 9904377 A SE9904377 A SE 9904377A SE 9904377 A SE9904377 A SE 9904377A SE 9904377 D0 SE9904377 D0 SE 9904377D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical combinations
combinations
present
pharmaceutical
provides novel
Prior art date
Application number
SE9904377A
Other languages
English (en)
Swedish (sv)
Inventor
John Dixon
Robert G Humphries
Gavin E Jarvis
Ian Kirk
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9904377A priority Critical patent/SE9904377D0/xx
Publication of SE9904377D0 publication Critical patent/SE9904377D0/xx
Priority to ARP000106143A priority patent/AR033658A1/es
Priority to CO00091389A priority patent/CO5271717A1/es
Priority to NZ518904A priority patent/NZ518904A/en
Priority to PL355841A priority patent/PL203430B1/pl
Priority to AT00982033T priority patent/ATE332698T1/de
Priority to RU2002117296/15A priority patent/RU2242232C2/ru
Priority to BR0016043-1A priority patent/BR0016043A/pt
Priority to NZ530058A priority patent/NZ530058A/en
Priority to MYPI20005578A priority patent/MY128896A/en
Priority to HU0203585A priority patent/HU230890B1/hu
Priority to DK00982033T priority patent/DK1237559T3/da
Priority to PCT/SE2000/002378 priority patent/WO2001039781A1/en
Priority to AU19109/01A priority patent/AU781691B2/en
Priority to EEP200200271A priority patent/EE05127B1/xx
Priority to KR1020027007026A priority patent/KR100785953B1/ko
Priority to MXPA02004871A priority patent/MXPA02004871A/es
Priority to JP2001541513A priority patent/JP2003515565A/ja
Priority to SK750-2002A priority patent/SK288707B6/sk
Priority to EP00982033A priority patent/EP1237559B1/en
Priority to EP06075955A priority patent/EP1719526A3/en
Priority to HK03100127.3A priority patent/HK1047893B/en
Priority to CN00816374A priority patent/CN1402639A/zh
Priority to US10/148,526 priority patent/US20030032618A1/en
Priority to IL14949500A priority patent/IL149495A0/xx
Priority to ES00982033T priority patent/ES2267591T3/es
Priority to SI200030885T priority patent/SI1237559T1/sl
Priority to CZ20021887A priority patent/CZ300925B6/cs
Priority to CA2391161A priority patent/CA2391161C/en
Priority to DE60029340T priority patent/DE60029340T2/de
Priority to PT00982033T priority patent/PT1237559E/pt
Priority to TW089125873A priority patent/TWI251491B/zh
Priority to ZA200203707A priority patent/ZA200203707B/xx
Priority to IS6398A priority patent/IS2841B/is
Priority to NO20022606A priority patent/NO331215B1/no
Priority to US11/441,278 priority patent/US20060270607A1/en
Priority to CY20061101267T priority patent/CY1105211T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9904377A 1999-12-01 1999-12-01 Pharmaceutical combinations SE9904377D0 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations
ARP000106143A AR033658A1 (es) 1999-12-01 2000-11-21 Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento d
PT00982033T PT1237559E (pt) 1999-12-01 2000-11-29 Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano
MXPA02004871A MXPA02004871A (es) 1999-12-01 2000-11-29 Combinaciones farmaceuticas.
EP00982033A EP1237559B1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran
PL355841A PL203430B1 (pl) 1999-12-01 2000-11-29 Zestaw leczniczy zawieraj acy antagonist e receptora P2T, zastosowanie antagonisty receptora P2T, preparat farmaceutyczny zawieraj acy antagonist e receptora P2T
AT00982033T ATE332698T1 (de) 1999-12-01 2000-11-29 Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
RU2002117296/15A RU2242232C2 (ru) 1999-12-01 2000-11-29 Фармацевтические комбинации
BR0016043-1A BR0016043A (pt) 1999-12-01 2000-11-29 Kit de partes, método para tratar trombose, uso de um antagonista de receptor p2t ou de um seu derivado farmaceuticamente aceitável, formulação farmacêutica, uso desta, processo para prepará-la, e, uso de um composto de fórmula ou de um seu derivado farmaceuticamente aceitável
NZ530058A NZ530058A (en) 1999-12-01 2000-11-29 A pharmaceutical combination comprising a P2T receptor antagonist, or a pharmaceutically acceptable salt thereof, and an anti-thrombotic agent, and the use of the combination in the treatment and prevention of thrombosis
MYPI20005578A MY128896A (en) 1999-12-01 2000-11-29 Pharmaceutical combinations
HU0203585A HU230890B1 (hu) 1999-12-01 2000-11-29 Egy P2T receptor antagonistát és melagatrant tartalmazó gyógyszerkombinációk
DK00982033T DK1237559T3 (da) 1999-12-01 2000-11-29 Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran
PCT/SE2000/002378 WO2001039781A1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations
AU19109/01A AU781691B2 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations
EEP200200271A EE05127B1 (et) 1999-12-01 2000-11-29 Osadest koosnev komplekt ja ravimpreparaat, mis sisaldavad P2T-retseptori antagonisti v?i selle farmatseutiliselt vastuv?etavat derivaati ja tromboosivastast ainet, ning nende kasutamine meditsiinis
KR1020027007026A KR100785953B1 (ko) 1999-12-01 2000-11-29 약학 조합제제
CO00091389A CO5271717A1 (es) 1999-12-01 2000-11-29 Combinaciones farmaceuticas
JP2001541513A JP2003515565A (ja) 1999-12-01 2000-11-29 薬剤の組合せ
SK750-2002A SK288707B6 (sk) 1999-12-01 2000-11-29 Farmaceutické kombinácie obsahujúce antagonistu P2T receptora a ďalšie antitrombotické činidlá, spôsob ich prípravy a ich použitie na liečenie a prevenciu trombózy
NZ518904A NZ518904A (en) 1999-12-01 2000-11-29 A pharmaceutical composition comprising a P2T receptor antagonist, or a pharmaceutically acceptable salt thereof, and an anti-thrombotic agent, and the use of the combination in the treatment and prevention of thrombosis
EP06075955A EP1719526A3 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations comprising a P2T receptor antagonist and another anti-thrombotic agent
HK03100127.3A HK1047893B (en) 1999-12-01 2000-11-29 Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran
CN00816374A CN1402639A (zh) 1999-12-01 2000-11-29 药用组合物
US10/148,526 US20030032618A1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations
IL14949500A IL149495A0 (en) 1999-12-01 2000-11-29 Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
ES00982033T ES2267591T3 (es) 1999-12-01 2000-11-29 Combinaciones farmaceuticas que comprenden un antagonista del receptor p2t y melagatran.
SI200030885T SI1237559T1 (sl) 1999-12-01 2000-11-29 Farmacevtska kombinacija vsebujoca p2t receptor antagonist in melagatran
CZ20021887A CZ300925B6 (cs) 1999-12-01 2000-11-29 Kit ze soucástí pro antitrombotickou terapii, antagonista receptoru P2T, farmaceutický prostredek a lécivo pro lécení trombózy
CA2391161A CA2391161C (en) 1999-12-01 2000-11-29 Pharmaceutical combinations comprising a p2t receptor antagonist and an anti-thrombotic agent
DE60029340T DE60029340T2 (de) 1999-12-01 2000-11-29 Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
TW089125873A TWI251491B (en) 1999-12-01 2000-12-05 Pharmaceutical combinations
ZA200203707A ZA200203707B (en) 1999-12-01 2002-05-09 Pharmaceutical combinations.
IS6398A IS2841B (is) 1999-12-01 2002-05-27 Samstæða hluta og lyfjasamsetningar
NO20022606A NO331215B1 (no) 1999-12-01 2002-05-31 Kit av deler og farmasoytiske formuleringer
US11/441,278 US20060270607A1 (en) 1999-12-01 2006-05-25 Pharmaceutical combinations
CY20061101267T CY1105211T1 (el) 1999-12-01 2006-09-05 Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
SE9904377D0 true SE9904377D0 (sv) 1999-12-01

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations

Country Status (32)

Country Link
US (2) US20030032618A1 (cs)
EP (2) EP1237559B1 (cs)
JP (1) JP2003515565A (cs)
KR (1) KR100785953B1 (cs)
CN (1) CN1402639A (cs)
AR (1) AR033658A1 (cs)
AT (1) ATE332698T1 (cs)
AU (1) AU781691B2 (cs)
BR (1) BR0016043A (cs)
CA (1) CA2391161C (cs)
CO (1) CO5271717A1 (cs)
CY (1) CY1105211T1 (cs)
CZ (1) CZ300925B6 (cs)
DE (1) DE60029340T2 (cs)
DK (1) DK1237559T3 (cs)
EE (1) EE05127B1 (cs)
ES (1) ES2267591T3 (cs)
HU (1) HU230890B1 (cs)
IL (1) IL149495A0 (cs)
IS (1) IS2841B (cs)
MX (1) MXPA02004871A (cs)
MY (1) MY128896A (cs)
NO (1) NO331215B1 (cs)
NZ (2) NZ530058A (cs)
PT (1) PT1237559E (cs)
RU (1) RU2242232C2 (cs)
SE (1) SE9904377D0 (cs)
SI (1) SI1237559T1 (cs)
SK (1) SK288707B6 (cs)
TW (1) TWI251491B (cs)
WO (1) WO2001039781A1 (cs)
ZA (1) ZA200203707B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
US20080226579A1 (en) * 2005-09-21 2008-09-18 Chong Kun Dang Pharmaceutical Corp. Novel Resinate Complex of S-Clopidogrel and Production Method Thereof
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PL2498731T3 (pl) 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
JP6247708B2 (ja) 2013-03-09 2017-12-13 キエージィ ファーマチェウティチ エス．ペー．アー． 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
CN110740736A (zh) 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
ATE127808T1 (de) * 1991-04-06 1995-09-15 Fisons Plc Atp-analogen.
CN1042430C (zh) * 1993-02-10 1999-03-10 英国阿斯特拉药品有限公司 N－烷基－2－取代的atp类似物、其制备方法和用途
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2226758A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
JPWO2005007191A1 (ja) * 2003-07-16 2006-08-31 協和醗酵工業株式会社 医薬組成物

Also Published As

Publication number Publication date
AU1910901A (en) 2001-06-12
HUP0203585A3 (en) 2005-01-28
SK7502002A3 (en) 2003-02-04
NZ530058A (en) 2005-04-29
NZ518904A (en) 2004-02-27
PT1237559E (pt) 2006-10-31
EP1719526A3 (en) 2007-04-25
SI1237559T1 (sl) 2007-02-28
NO20022606L (no) 2002-07-11
NO20022606D0 (no) 2002-05-31
CY1105211T1 (el) 2010-03-03
CO5271717A1 (es) 2003-04-30
MY128896A (en) 2007-02-28
US20060270607A1 (en) 2006-11-30
EP1719526A2 (en) 2006-11-08
PL355841A1 (en) 2004-05-17
KR100785953B1 (ko) 2007-12-14
CA2391161A1 (en) 2001-06-07
AR033658A1 (es) 2004-01-07
HK1047893A1 (en) 2003-03-14
RU2002117296A (ru) 2004-01-20
CZ20021887A3 (cs) 2002-11-13
HU230890B1 (hu) 2018-12-28
IL149495A0 (en) 2004-03-28
SK288707B6 (sk) 2019-10-02
ZA200203707B (en) 2003-10-29
KR20020069201A (ko) 2002-08-29
EE05127B1 (et) 2009-02-16
RU2242232C2 (ru) 2004-12-20
ATE332698T1 (de) 2006-08-15
ES2267591T3 (es) 2007-03-16
EP1237559A1 (en) 2002-09-11
HUP0203585A2 (hu) 2003-03-28
DE60029340D1 (de) 2006-08-24
WO2001039781A1 (en) 2001-06-07
EE200200271A (et) 2003-06-16
IS2841B (is) 2013-08-15
DE60029340T2 (de) 2007-07-19
EP1237559B1 (en) 2006-07-12
CA2391161C (en) 2010-10-05
CZ300925B6 (cs) 2009-09-09
CN1402639A (zh) 2003-03-12
TWI251491B (en) 2006-03-21
US20030032618A1 (en) 2003-02-13
NO331215B1 (no) 2011-11-07
MXPA02004871A (es) 2002-08-30
AU781691B2 (en) 2005-06-09
JP2003515565A (ja) 2003-05-07
DK1237559T3 (da) 2006-10-30
BR0016043A (pt) 2002-07-23
IS6398A (is) 2002-05-27

Similar Documents

Publication Publication Date Title
SE9904377D0 (sv) Pharmaceutical combinations
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
NO996269D0 (no) Quinolin-indol antimikrobielle midler, samt anvendelse og blandinger derav
ATE231872T1 (de) Thiazolopyrimidinderivate
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
TR200100054T2 (tr) Paroksetin metansülfonat
DE60134126D1 (de) 17-alpha-substituierte-11-beta-substituierte-4-aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität
PT1224205E (pt) Derivados 5-beta-sapogenina e pseudo-sapogenina e sua utilizacao no tratamento de demencia
NO20005179D0 (no) Medikament behandling
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
BR0208971B1 (pt) produto absorvente com ajuste melhorado.
BR0208970B1 (pt) produto absorvente com ajuste melhorado.
BR0208969B1 (pt) produto absorvente com ajuste melhorado.
SE9802937D0 (sv) Novel compounds
ATE365748T1 (de) Polymer-konjugate von neublastin und methoden für deren verwendung
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
BR0012043B1 (pt) composiÇço de tratamento de cabelo.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
EP1038958A4 (en) HUMAN NAP1 PROTEIN
NO20005548D0 (no) Mykobakterieinhibitorer
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
FI20012016L (fi) Eettereitä hajottavia bakteereita ja niiden käyttö